Neovasc Inc. (NVCN)

4.10
0.02 0.44
NASDAQ : Health Technology
Prev Close 4.08
Open 4.05
Day Low/High 4.05 / 4.16
52 Wk Low/High 0.47 / 45.80
Volume 107.59K
Avg Volume 474.40K
Exchange NASDAQ
Shares Outstanding 7.48M
Market Cap 30.25M
EPS -76.30
P/E Ratio 4.26
Div & Yield N.A. (N.A)

Latest News

The European Society Of Cardiology Includes Neovasc Reducer™ For The Treatment Of Refractory Angina In The European Practice Guidelines For The Diagnosis And Management Of Chronic Coronary Syndromes

The European Society Of Cardiology Includes Neovasc Reducer™ For The Treatment Of Refractory Angina In The European Practice Guidelines For The Diagnosis And Management Of Chronic Coronary Syndromes

Announcement Made at European Society of Cardiology Congress 2019 in Paris, France NASDAQ, TSX: NVCN VANCOUVER, Sept.

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency

NASDAQ, TSX: NVCN VANCOUVER, Aug. 22, 2019 /PRNewswire/ - ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the...

Neovasc Announces Second Quarter 2019 Financial Results

Neovasc Announces Second Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights Received Guidance from FDA to explore a potential Humanitarian Device Exemption Pathway for Neovasc Reducer™ (the "Reducer") for CCS class IV patients and to meet for another Sprint discussion Closed Private Placement...

Neovasc To Attend Canaccord Genuity 39th Annual Growth Conference

Neovasc To Attend Canaccord Genuity 39th Annual Growth Conference

Presentation Scheduled for 11:30 am Eastern Time on August 8 th NASDAQ, TSX: NVCN VANCOUVER, Aug.

Neovasc To Announce Second Quarter 2019 Financial Results On Wednesday, August 7th

Neovasc To Announce Second Quarter 2019 Financial Results On Wednesday, August 7th

Conference Call Scheduled for 4:30 pm Eastern Time on August 7 th NASDAQ, TSX: NVCN VANCOUVER, Aug.

Neovasc Regains Compliance With Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

Neovasc Regains Compliance With Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

NASDAQ, TSX: NVCN VANCOUVER, July 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Participates In Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing Of Prosthetic Heart Valves

Neovasc Participates In Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing Of Prosthetic Heart Valves

Company Joined by Other Industry Leaders as Part of ISO Cardiac Valves Working Group NASDAQ, TSX: NVCN VANCOUVER, July 15, 2019 /PRNewswire/ - Neovasc, Inc.

Neovasc To Explore HDE Approval Pathway And Alternate Trial Designs For The Reducer Following Guidance From The FDA

Neovasc To Explore HDE Approval Pathway And Alternate Trial Designs For The Reducer Following Guidance From The FDA

NASDAQ, TSX: NVCN VANCOUVER, July 12, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Effective Date Of Share Consolidation

Neovasc Announces Effective Date Of Share Consolidation

NASDAQ, TSX: NVCN VANCOUVER, June 28, 2019 /PRNewswire/ - Neovasc Inc. (" Neovasc" or the " Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development...

Neovasc Announces Presentations On Tiara™ For Treatment Of Mitral Regurgitation And Reducer™ For Treatment Of Refractory Angina At The CSI Frankfurt 2019 Conference

Neovasc Announces Presentations On Tiara™ For Treatment Of Mitral Regurgitation And Reducer™ For Treatment Of Refractory Angina At The CSI Frankfurt 2019 Conference

NASDAQ, TSX: NVCN VANCOUVER, June 27, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Regains Compliance With Nasdaq Minimum Market Value Rule

Neovasc Regains Compliance With Nasdaq Minimum Market Value Rule

NASDAQ, TSX: NVCN VANCOUVER, June 25, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Tiara™ Featured In Presentation At 11th Annual TVT 2019

Tiara™ Featured In Presentation At 11th Annual TVT 2019

NASDAQ, TSX: NVCN VANCOUVER, June 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Nasdaq Continuing To Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

Neovasc Announces Nasdaq Continuing To Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

NASDAQ, TSX: NVCN VANCOUVER, June 7, 2019 /PRNewswire/ -  Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of listed securities ("MVLS") of over US$35 million,...

Neovasc Inc. Reports Results Of Annual General And Special Meeting Of Shareholders And Provides Update On Neovasc Reducer™

Neovasc Inc. Reports Results Of Annual General And Special Meeting Of Shareholders And Provides Update On Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, June 4, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on...

Neovasc Announces Publication Of Peer-Reviewed Article In European Heart Journal Concluding Positive Cost-Effectiveness Of The Neovasc Reducer™

Neovasc Announces Publication Of Peer-Reviewed Article In European Heart Journal Concluding Positive Cost-Effectiveness Of The Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, May 28, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

New Tiara And Reducer Data Presented In Several Presentations At The EuroPCR 2019 Conference In Paris

New Tiara And Reducer Data Presented In Several Presentations At The EuroPCR 2019 Conference In Paris

NASDAQ, TSX: NVCN VANCOUVER, May 23, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Positive Two-Year Follow-up Safety And Efficacy Data For The Neovasc Reducer™ In A Peer Reviewed Article In The International Journal Of Cardiology

Neovasc Announces Positive Two-Year Follow-up Safety And Efficacy Data For The Neovasc Reducer™ In A Peer Reviewed Article In The International Journal Of Cardiology

NASDAQ, TSX: NVCN VANCOUVER, May 22, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Closing Of Private Placement Of Convertible Debt And Common Shares For Gross Proceeds Of US$11.5 Million

Neovasc Announces Closing Of Private Placement Of Convertible Debt And Common Shares For Gross Proceeds Of US$11.5 Million

NASDAQ, TSX: NVCN VANCOUVER, May 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX:NVCN) announced today that it has closed its previously announced private placement (the "Private Placement") of (i) a 15% original issue...

Neovasc Announces Private Placement Of Convertible Debt And Equity For Gross Proceeds Of US$11.5 Million

Neovasc Announces Private Placement Of Convertible Debt And Equity For Gross Proceeds Of US$11.5 Million

Upon closing of this agreement, cash and cash equivalents is expected to support operations into Q1 2020 NASDAQ, TSX: NVCN VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc.

Neovasc Announces First Quarter 2019 Financial Results

Neovasc Announces First Quarter 2019 Financial Results

NASDAQ, TSX: NVCN Recent Highlights Announced the 1,000 th recipient of a Neovasc Reducer TM ("Reducer") implant Company sponsored Reducer Symposium attended by over 100 attendees at the 85th Annual Conference of the German Society of Cardiology ("DGK")...

Neovasc Announces Treatment Of 1,000th Refractory Angina Patient With Neovasc Reducer™

Neovasc Announces Treatment Of 1,000th Refractory Angina Patient With Neovasc Reducer™

NASDAQ, TSX: NVCN VANCOUVER, May 6, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc To Announce First Quarter 2019 Financial Results On Thursday, May 9th

Neovasc To Announce First Quarter 2019 Financial Results On Thursday, May 9th

Conference Call Scheduled for 4:30 pm Eastern Time on May 9 th   NASDAQ, TSX: NVCN VANCOUVER, May 3, 2019 /PRNewswire/ - Neovasc, Inc.

Neovasc Provides Highlights From Annual Conference Of The DGK, The German Society Of Cardiology; Symposium Generates Growing Support For Reducer

Neovasc Provides Highlights From Annual Conference Of The DGK, The German Society Of Cardiology; Symposium Generates Growing Support For Reducer

NASDAQ, TSX: NVCN VANCOUVER, April 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Resolution Of Last Remaining Active Litigation

Neovasc Announces Resolution Of Last Remaining Active Litigation

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

Neovasc Announces Peer Reviewed Publication In The International Journal Of Cardiology Demonstrating That The Neovasc Reducer™ Improves Diastolic Function In Patients Suffering From Severe Angina

Neovasc Announces Peer Reviewed Publication In The International Journal Of Cardiology Demonstrating That The Neovasc Reducer™ Improves Diastolic Function In Patients Suffering From Severe Angina

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of...

How to Trade Wednesday's Most Active Stocks - Sprint, AMD, ArcelorMittal and More

How to Trade Wednesday's Most Active Stocks - Sprint, AMD, ArcelorMittal and More

Here's a technical look on how to trade some of the most active stocks on the market today.